Global Diabetic Neuropathy Market

Diabetic Neuropathy Market Size, Share, Growth Analysis, By Disorder(Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Distribution channel(Hospitals, Clinics, Retail Pharmacy, Online Pharmacy), By Drug Class(Anti-Depressants, Anti-Seizures, Opioid, Non-Steroidal Anti-Inflammatory), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2245 | Region: Global | Published Date: February, 2024
Pages: 165 | Tables: 94 | Figures: 76

Diabetic Neuropathy Market Insights

Global Diabetic Neuropathy Market size was valued at USD 3626.38 million in 2019 and is poised to grow from USD 3876.6 million in 2023 to USD 7067.25 million by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

A condition that damages the nerves and is connected to hyperglycemia is diabetic neuropathy. Although diabetic neuropathies' symptoms could not be detected early on, people who have had diabetes for a long period are more likely to experience nerve damage across their bodies. Since diabetic neuropathy cannot be cured, it can be controlled or avoided with the help of a variety of therapeutic approaches. Because of the disease's complexity, regulating agencies are required to authorize additional products and therapy methods that are related to it. Numerous expansion prospects will arise for the businesses operating in this market as a result of the high occurrence of diabetic neuropathy, which affects mainly diabetic individuals.

US Diabetic Neuropathy Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Diabetic Neuropathy Market size was valued at USD 3626.38 million in 2019 and is poised to grow from USD 3876.6 million in 2023 to USD 7067.25 million by 2031, growing at a CAGR of 6.9% in the forecast period (2024-2031).

Due to the rise in R&D projects, Johnson & Johnson and GlaxoSmithKline plc are the major players outperforming the diabetic neuropathy market. Major market companies are being influenced by this to diversify their product offerings globally. As a result, the important companies' varied product portfolios tend to increase the company's value. For instance, The most significant player in the market is thought to be Pfizer Inc. due to its emphasis on creating goods like Motrin and Lyrica that are expected to fuel growth. 'Johnson & Johnson ', 'Pfizer Inc ', 'Eli Lilly and Company', 'Boehringer Ingelheim International GmbH', 'GlaxoSmithKline plc', 'Astellas Pharma Inc.', 'Novartis AG', 'Sanofi S.A.', 'Teva Pharmaceutical Industries Ltd.', 'Merck & Co., Inc.', 'AbbVie Inc.', 'Glenmark Pharmaceuticals Limited', 'Lupin Pharmaceuticals, Inc.', 'Intas Pharmaceuticals Ltd.', 'Alkem Laboratories Ltd.', 'Cipla Limited', 'Mylan N.V.', 'Zydus Cadila Healthcare Limited', 'Sun Pharmaceutical Industries Ltd.', 'Dr. Reddy's Laboratories Ltd.'

Rise in prevalence of diabetes to cause a rise in the demand for diabetic neuropathy.

During the forecast year, high-tech goods will be developed for better diabetic neuropathy therapy. Companies are concentrating on creating transdermal patches, mouthwash, talc, as well as other products.  Manufacturers have introduced cutting-edge medication delivery systems, like syringe-free injection equipment, to combat problems related to surgical pharmaceuticals. As a result, NFIT has attracted significant interest in the treatment of the disease, which is helping the market expand. As a result, the market is expanding due to the rising demand for new drug delivery methods such as oral, transdermal, parenteral, and inhalation.

In 2021, the greatest market for diabetic neuropathy is in North America. In order to counteract the degradation of generic pharmaceuticals, pharma companies continue to give fresh medications in the area. Due to a big incidence of chronic diseases such as diabetes, and an increasing senior generation, diabetic neuropathy treatment has become extremely popular, particularly in the United States.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Diabetic Neuropathy Market

Report ID: SQMIG35I2245

$5,300
BUY NOW GET FREE SAMPLE